Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation

Title: Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation

Volume: 17 Issue: 1

Author(s): Ashley M. Miller and Iain B. McInnes

Affiliation:

Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae

Abstract: Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.

Cite this article as:

M. Miller Ashley and B. McInnes Iain, Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation, Current Pharmaceutical Design 2011; 17 (1) . https://dx.doi.org/10.2174/138161211795049796